BridgeBio Pharma (BBIO) Interest & Investment Income (2018 - 2026)

BridgeBio Pharma has disclosed Interest & Investment Income across 9 years of filings, most recently posting $6.2 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $6.2 million, up 15.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.7 million (up 11.62% YoY), and the FY2025 annual result was $19.9 million, up 15.1% from the prior year.
• Interest & Investment Income came in at $6.2 million for Q1 2026 at BridgeBio Pharma, up from $4.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.2 million in Q1 2026 to a low of $267000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $4.2 million (2023), against an average of $4.1 million.
• Peak annual rise in Interest & Investment Income reached 2148.35% in 2022, while the deepest fall reached 32.23% in 2022.
• BridgeBio Pharma's Interest & Investment Income stood at $4.1 million in 2022, then surged by 36.31% to $5.6 million in 2023, then retreated by 16.05% to $4.7 million in 2024, then slipped by 7.5% to $4.3 million in 2025, then surged by 44.18% to $6.2 million in 2026.
• The last three Interest & Investment Income figures came in at $6.2 million (Q1 2026), $4.3 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.